|
|
Research & Development |
| Allermed is a leader in the development of biologics that induce a cellular immune response. A delayed-type skin test antigen of Leishmania tropica is in Phase II development. Clinical trials are being conducted on the treatment of Verruca vulgaris by activating an immune response intralesionally with a biologic product derived from the yeast Candida albicans. |
Testimonial
"I was very happy to have worked with Allermed on the development of spherule-based coccidioidin. The return of this product to the market will provide clinicians with a valuable tool in the diagnosis and management of coccidioidomycosis."
Neil M. Ampel, M.D.
Professor of Medicine
University of Arizona |
|
| |
|
